Clinical benefits of Cerebrolysin treatment in the real world – recovery after delirium

Dr. Alansary discussed delirium in ICU patients, a common complication associated with increased mortality. He highlighted the potentialyl protective role of Cerebrolysin in reducing BBB breakdown and inflammation.

Case Summary
A 70-year-old male with advanced COPD, hypertension, diabetes, ischemic heart disease and a history of smoking was admitted with respiratory failure and altered mental status. He exhibited hypoxia, hypercapnia and signs of multiorgan dysfunction. Imaging confirmed severe COPD with right-sided consolidation. Blood cultures later revealed Streptococcus pneumoniae.

Management
The patient received non-invasive ventilation, beta-lactam antibiotics, bronchodilators, steroids and supportive care. Delirium risk factors included age, hypoxia, infection and ICU environment. CAM-ICU scores were used to monitor delirium, with environmental modifications, early mobilization, minimal sedation and low-dose olanzapine implemented.

Cerebrolysin Administration and Outcome
Cerebrolysin (30 ml in 500 ml over 2–3 hours) was administered. The patient showed gradual improvement in respiratory function and delirium, with CAM-ICU scores negative by day six. Functional recovery was significantly  faster compared with ICU patients not receiving Cerebrolysin.

Conclusion
Dr. Alansary concluded that delirium is a significant ICU challenge and that Cerebrolysin may serve as a useful adjuvant therapy to accelerate recovery. Further studies are planned to confirm efficacy in larger patient cohorts.